Tech and biotech bets aiming to outpace the market in 2026: Alphabet, BeOne Medicines, and Rhythm
A market outlook piece argues three catalysts could help stocks beat the S&P 500 in 2026: Alphabet (GOOGL/GOOG) propelled by Google Cloud backlog growth and AI initiatives like Gemini 3.0; BeOne Medicines (ONC) with Brukinsa’s continued uptake and potential regulatory milestones for sonrotoclax and BGB-16673; and Rhythm Pharmaceuticals (RYTM) amid an FDA decision on Imcivree for acquired hypothalamic obesity (by March 20, 2026) plus additional Phase 3 data and other developments in 2026.